EGFR and diabetes mellitus: Alternatively, SF might be used in place of conventional ligand-activation based therapeutic strategies to stimulate EGFR signaling in diabetes-induced cardiac dysfunction which results from depressed EGFR-ERK1/2 phosphorylation [34].